Heartbeam, Inc. (BEAT) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Heartbeam, Inc. on June 22, 2026, covering events occurring on June 15, 2026. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Santa Clara, California. The report focuses on Item 5.02 regarding compensatory arrangements for Named Executive Officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding executive compensation and does not contain periodic financial statements.
Material Changes and Executive Compensation
On June 15, 2026, the Compensation Committee approved new compensatory arrangements for Branislav Vajdic, President, Founder, and Director:
- Performance-Based Restricted Stock Units (PRSUs): An award of 2,800,000 PRSUs under the 2022 Equity Incentive Plan. Vesting is contingent upon specified operational, software, product-development, and clinical study milestones within one year, alongside service-based conditions over three years. Accelerated vesting applies in the event of a Change in Control or qualifying termination.
- Transaction Bonus Agreement: A bonus payable upon a Qualifying Change in Control, contingent on Dr. Vajdic's continued employment. The bonus amount is determined by achieving specific market capitalization and per-share price thresholds. Payment will generally match the form of consideration paid to stockholders, with a Board option to pay in cash.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or general outlook commentary. The primary risk highlighted is the contingent nature of the executive compensation, which relies on the achievement of specific clinical and operational milestones and the occurrence of a Change in Control meeting specific market valuation thresholds.
Investor Verification Checklist
- Review the full text of the PRSU Award Agreement (Exhibit 10.1) to understand specific performance milestones.
- Review the Transaction Bonus Agreement (Exhibit 10.2) to verify the specific market capitalization and per-share price thresholds required for payout.
- Monitor future filings for updates on the achievement of the clinical study and product-development milestones.
- Verify the Company's status as an emerging growth company and any implications for financial reporting standards.